However, EIF4A3 phosphorylation in other tumors, such as renal cancer and malignant hematological diseases, has not been investigated, while the signaling pathways in HCC, breast cancer, lung cancer, and other tumors are poorly understood. This evidence concerns the gene EIF4A3 and breast carcinoma.